Table 3.
Prevalence of use of respiratory medications within 12 months before the index date among new users of aclidinium, aclidinium/formoterol and other COPD medications: patients with COPD aged 40 years or older
| Data source and comedication | Aclidinium, % | Aclidinium/ formoterol, % |
Tiotropium, % | Other LAMA, % | LAMA/LABA, % | LABA, % | LABA/ICS, % |
|---|---|---|---|---|---|---|---|
| CPRD, UK | N = 4307 | N = 1942 | N = 16,891 | N = 11,437 | N = 6504 | N = 21,458 | N = 3549 |
| Aclidinium | 5.7 | 16.9 | 3.1 | 5.5 | 5.4 | 3.7 | 3.9 |
| Aclidinium/formoterol | 2.2 | 0.3 | 0.5 | 0.9 | 3.0 | 1.2 | 0.9 |
| Tiotropium | 40.3 | 43.7 | 27.1 | 45.5 | 44.8 | 36.5 | 37.3 |
| Other LAMA | 6.4 | 7.6 | 3.4 | 1.8 | 16.7 | 4.7 | 6.7 |
| LAMA/LABA | 1.7 | 7.6 | 1.5 | 5.1 | 0.2 | 3.3 | 2.0 |
| LABA | 5.2 | 13.9 | 5.1 | 4.8 | 13.5 | 8.9 | 18.7 |
| LABA/ICS | 60.6 | 38.4 | 50.3 | 59.3 | 35.8 | 34.4 | 21.5 |
| SABA | 83.3 | 84.4 | 77.4 | 84.1 | 81.3 | 79.8 | 81.2 |
| Oral corticosteroids | 49.8 | 40.9 | 44.1 | 48.2 | 41.8 | 45.0 | 36.8 |
| Mucolytics | 15.3 | 13.3 | 11.4 | 14.6 | 13.4 | 10.5 | 7.5 |
| Antihistamines | 15.0 | 13.0 | 14.4 | 13.2 | 11.9 | 14.6 | 11.5 |
| ICS | 7.8 | 7.8 | 9.7 | 7.4 | 7.4 | 18.9 | 16.6 |
| SAMA | 7.2 | 2.9 | 6.1 | 4.3 | 4.3 | 4.8 | 5.3 |
| Cough and cold preparations | 7.8 | 7.4 | 8.2 | 7.0 | 7.1 | 8.1 | 7.2 |
| Xanthines | 4.3 | 2.7 | 3.6 | 4.5 | 2.6 | 2.8 | 1.7 |
| National Health Databases, Denmark | N = 1575 | N = 1490 | N = 24,229 | N = 3567 | N = 22,369 | N = 31,130 | N = 11,443 |
| Aclidinium | 17.4 | 14.0 | 1.6 | 2.8 | 1.6 | 1.5 | 1.3 |
| Aclidinium/formoterol | 1.8 | 0 | 0.5 | 0.9 | 1.0 | 0.5 | 0.5 |
| Tiotropium | 27.3 | 36.4 | 33.7 | 27.8 | 48.1 | 35.5 | 36.4 |
| Other LAMA | 4.6 | 3.6 | 2.0 | 8.6 | 4.7 | 1.8 | 2.3 |
| LAMA/LABA | 8.3 | 23.3 | 8.3 | 15.3 | 4.2 | 8.4 | 8.5 |
| LABA | 12.6 | 19.5 | 12.1 | 17.6 | 22.0 | 13.2 | 24.9 |
| LABA/ICS | 62.5 | 42.1 | 51.1 | 56.0 | 42.8 | 39.7 | 30.1 |
| SABA | 60.4 | 57.4 | 53.1 | 57.7 | 55.6 | 51.4 | 47.9 |
| Oral corticosteroids | 37.6 | 36.0 | 33.0 | 38.7 | 35.4 | 30.6 | 27.5 |
| Mucolytics | 5.2 | 4.6 | 4.4 | 3.9 | 4.2 | 3.9 | 3.5 |
| Antihistamines | 15.9 | 12.6 | 11.9 | 12.6 | 10.6 | 13.3 | 12.1 |
| ICS | 11.9 | 14.6 | 10.8 | 12.8 | 11.4 | 15.2 | 16.4 |
| SAMA | 0.8 | 0.5 | 0.5 | 0.4 | 0.5 | 0.4 | 0.5 |
| Cough and cold preparations | 11.1 | 12.8 | 10.4 | 10.4 | 10.3 | 11.1 | 11.0 |
| Xanthines | 1.5 | 0.9 | 1.2 | 1.3 | 1.0 | 1.1 | 0.9 |
| GePaRD, Germany | N = 8567 | N = 9243 | N = 29,468 | N = 5135 | N = 18,601 | N = 91,164 | N = 27,981 |
| Aclidinium | 9.9 | 22.6 | 3.8 | 4.2 | 5.4 | 1.7 | 3.5 |
| Aclidinium/formoterol | 1.2 | 0.0 | 0.9 | 1.0 | 1.9 | 0.4 | 0.7 |
| Tiotropium | 13.8 | 24.6 | 12.6 | 12.6 | 34.2 | 8.7 | 17.7 |
| Other LAMA | 2.6 | 4.3 | 2.3 | 9.0 | 7.1 | 1.2 | 2.3 |
| LAMA/LABA | 3.7 | 9.8 | 4.8 | 6.9 | 3.4 | 2.0 | 4.1 |
| LABA | 17.7 | 34.4 | 15.1 | 16.4 | 26.0 | 7.3 | 16.8 |
| LABA/ICS | 36.4 | 30.5 | 38.3 | 37.3 | 33.5 | 20.7 | 20.5 |
| SABA | 33.7 | 40.9 | 34.5 | 35.2 | 37.9 | 25.7 | 30.8 |
| Oral corticosteroids | 27.8 | 31.1 | 30.6 | 28.8 | 31.5 | 21.5 | 23.9 |
| Mucolytics | 4.8 | 5.4 | 4.8 | 4.4 | 5.4 | 3.1 | 3.7 |
| Antihistamines | 2.9 | 2.2 | 3.1 | 2.6 | 2.5 | 3.9 | 2.9 |
| ICS | 13.1 | 17.3 | 11.7 | 11.8 | 14.0 | 11.7 | 18.2 |
| SAMA | 3.3 | 4.0 | 4.0 | 3.5 | 4.4 | 1.6 | 2.5 |
| Cough and cold preparations | 11.1 | 10.2 | 10.3 | 11.3 | 10.6 | 13.5 | 10.4 |
| Xanthines | 4.5 | 5.6 | 5.2 | 4.9 | 5.6 | 2.3 | 3.2 |
COPD chronic obstructive pulmonary disease, CPRD Clinical Practice Research Datalink, GePaRD German Pharmacoepidemiological Research Database, ICS inhaled corticosteroids, LABA inhaled long-acting beta2-agonist, LAMA long-acting muscarinic antagonists, SABA short-acting beta-2-agonist, SAMA short-acting muscarinic antagonists, UK United Kingdom